Journal article
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
- Abstract:
-
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis. Here we report the final analysis of Oral Psoriatic Arthritis Trial (OPAL) Balance, a 36-month long-term extension study, with a 12-month methotrexate withdrawal substudy, that assessed tofacitinib safety, tolerability, and efficacy in patients with active psoriatic arthritis.
Methods For this open-label, long-term extension study, which was run at 12...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Rheumatology Journal website
- Volume:
- 3
- Issue:
- 4
- Pages:
- e270-e283
- Publication date:
- 2021-03-24
- Acceptance date:
- 2021-01-08
- DOI:
- EISSN:
-
1474-547X
- ISSN:
-
0140-6736
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1156932
- Local pid:
- pubs:1156932
- Deposit date:
- 2021-01-18
Terms of use
- Copyright holder:
- Elsevier Ltd.
- Copyright date:
- 2021
- Rights statement:
- © 2021 Elsevier Ltd. All rights reserved.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Elsevier at https://doi.org/10.1016/S2665-9913(21)00010-2
If you are the owner of this record, you can report an update to it here: Report update to this record